Jiangsu Vcare Secures Over CNY 450 Million in Series C Funding
Published Time:
2024-01-02 17:34
Source:
Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) closed its Series C financing round, raising over CNY 450 million. The investment consortium included China Life Private Equity Investment, DYEE Capital, Hongyao Technology Capital, existing investor Nanjing Innovation Capital Group, and Hangzhou Huadian Investment. The participation of new investors alongside continued support from existing shareholders demonstrates strong market confidence in Jiangsu Vcare’s growth trajectory. Proceeds will accelerate the advancement of its innovative drug pipeline and strengthen its integrated CRO/CDMO services across the pharmaceutical value chain.
The successful Series C closing amid challenging market conditions underscores Jiangsu Vcare’s robust development potential and competitive advantages. Since its inception, the company has pursued a dual-core strategy: proprietary innovative drug development and comprehensive CRO/CDMO services. This approach prioritizes independent innovation and client-centric solutions. Currently, both business pillars demonstrate rapid growth: Multiple clinical-stage drug candidates approaching key milestones; Sustained expansion of CRO/CDMO business; Established a fortified competitive "moat" through differentiated products, technologies, and services; With robust investor backing, Jiangsu Vcare is positioned to achieve high-quality development.
Dr. Gong Yanchun, Co-founder and CEO, stated: "We view financing not merely as capital-raising, but as forging a shared-destiny partnership with values-aligned, committed, and professional collaborators to achieve meaningful impact. Securing this round during the industry-wide 'winter' reflects capital markets’ recognition of Vcare’s team and vision. At this new developmental stage, we remain steadfastly focused on our dual-core strategy. Through differentiated approaches and by seizing policy and market opportunities, we will advance courageously and steadily in innovative drug R&D and pharmaceutical services. While accelerating our own high-quality growth, we are committed to contributing to the pharmaceutical industry’s sustainable advancement."
Related News
28
2025
/
11
Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) announced that the Phase II clinical study of VC005 topical gel, a self-developed second-generation highly selective JAK1 inhibitor, for the treatment of mild-to-moderate atopic dermatitis (AD) in adults in China has successfully completed unblinding and preliminary analysis, yielding positive results.
View Details
11
2025
/
11
Recently, Eratrectinib (VC004), a next-generation TRK inhibitor independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare), was included in the " Support Anti-tumor drugR&D for Kids (SPARK Plan)" launched by the CDE of the NMPA, become the 5th innovative drug variety in the country to be included in this program. This important progress will accelerate the R&D process of the domestic new anticancer drug Eratrectinib in the field of pediatric oncology, bringing new hope to pediatric oncology patients in China.
View Details
31
2025
/
10
Recently, Jiangsu Vcare PharmaTech Co.,Ltd. (Jiangsu Vcare) announced the completion of first patient enrollment in the Phase Ⅱ clinical trial of VC005 Tablets. This independently developed next-generation highly selective JAK1 inhibitor is being evaluated for the oral treatment of non-segmental vitiligo (NSV). The trial aims to assess the efficacy, safety, and PK profile of VC005 Tablets in Chinese adult NSV patients, providing a basis for the selection of dosage in subsequent clinical studies.
View Details
29
2025
/
09
Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) has achieved a major milestone in the Phase Ⅲ clinical trial of VC005 Tablets – the company's independently developed second-generation highly selective JAK1 inhibitor for oral treatment of moderate-to-severe atopic dermatitis (AD) – with the successful completion of full patients enrollment. This multicenter, randomized, double-blind, placebo-controlled pivotal Phase Ⅲ study aims to further validate the efficacy and safety of VC005 Tablets in adult patients with moderate-to-severe AD. The smooth completion of enrollment marks a crucial step forward for this innovative drug towards clinical application.
View Details
15
2025
/
09
Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) announced the official initiation of the Phase III clinical trial of VC005 Tablets—a self-developed second-generation highly selective JAK1 inhibitor—for the oral treatment of ankylosing spondylitis (AS). This marks the second Phase III clinical trial of VC005 Tablets, following the one for oral treatment of moderate-to-severe atopic dermatitis (AD), signifying that the AS indication has entered the confirmatory clinical research stage.
View Details
12
2025
/
09
Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) officially initiated the Phase II clinical trial of VC005 Tablets, a second-generation highly selective JAK1 inhibitor independently developed by the company, for a new oral indication – the treatment of non-segmental vitiligo (NSV).
View Details
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
Powerby：www.300.cn nanjing.300.cn